Checkpoint Therapeutics Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $41.58 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Checkpoint Therapeutics Inc had its IPO on 2017-06-26 under the ticker symbol CKPT.
The company operates in the Healthcare sector and Biotechnology industry. Checkpoint Therapeutics Inc has a staff strength of 14 employees.
Shares of Checkpoint Therapeutics Inc opened at $3.6 at the start of the last trading session i.e. 2023-03-24.
The stocks traded within a range of $3.45 - $3.8, and closed at $3.72.
This is a +3.62% increase from the previous day's closing price.
A total volume of 120,095 shares were traded at the close of the day’s session.
In the last one week, shares of Checkpoint Therapeutics Inc have slipped by -6.77%.
Checkpoint Therapeutics Inc's Key Ratios
Checkpoint Therapeutics Inc has a market cap of $41.58 million, indicating a price to book ratio of 8.5555 and a price to sales ratio of 277.6681.
In the last 12-months Checkpoint Therapeutics Inc’s revenue was $134000 with a gross profit of $-48185000 and an EBITDA of $0. The EBITDA ratio measures Checkpoint Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Checkpoint Therapeutics Inc’s operating margin was -53327.61% while its return on assets stood at -108.15% with a return of equity of -306.03%.
In Q3, Checkpoint Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 65.5%.
Checkpoint Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-9.01 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Checkpoint Therapeutics Inc’s profitability.
Checkpoint Therapeutics Inc stock is trading at a EV to sales ratio of 105.4105 and a EV to EBITDA ratio of -0.1977. Its price to sales ratio in the trailing 12-months stood at 277.6681.
Checkpoint Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $21.62 million
- Total Liabilities
- $22.96 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Checkpoint Therapeutics Inc ended 2023 with $21.62 million in total assets and $0 in total liabilities. Its intangible assets were valued at $21.62 million while shareholder equity stood at $-1335000.00.
Checkpoint Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $22.96 million in other current liabilities, 10000.00 in common stock, $-241464000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $20.48 million and cash and short-term investments were $20.48 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
Checkpoint Therapeutics Inc’s total current assets stands at $21.62 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $48000.00 compared to accounts payable of $14.16 million and inventory worth $0.
In 2023, Checkpoint Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Checkpoint Therapeutics Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Checkpoint Therapeutics Inc stock is currently trading at $3.72 per share. It touched a 52-week high of $19 and a 52-week low of $19. Analysts tracking the stock have a 12-month average target price of $54.6.
Its 50-day moving average was $4.96 and 200-day moving average was $8.43 The short ratio stood at 2.96 indicating a short percent outstanding of 0%.
Around 2158.4% of the company’s stock are held by insiders while 2597.5% are held by institutions.
Frequently Asked Questions About Checkpoint Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company’s lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.